

Special Issue

Precision Medicine for Immunology and Immunogenetics

Message from the Guest Editor

Immunity is the capability of an organism to resist harmful invaders using both specific and non-specific components. This can be done by either preventing their entrance or elimination following successful invasion. The immune system also acts against diseases, including cancer, being capable of eliminating them, even though certain types of cancer and cancer treatments may weaken or evade immune response. Inflammation due to cancer may contribute to genomic instability, epigenetic modification, proliferation and anti-apoptotic mechanism enhancement, angiogenesis, and tumor dissemination, thus leading to high metastatic potential. Immunogenetics, which studies the molecular and genetic basis of the immune response, is a new, but rapidly expanding scientific discipline to study immunological pathways and polymorphisms that affect the ability to control infectious diseases, autoimmunity or cancer, aiming at the identification of new therapeutic targets.

Guest Editor

Dr. Ippokratis Messaritakis
Faculty of Medicine, University of Crete, 74100 Crete, Greece

Deadline for manuscript submissions

closed (22 March 2022)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/59855

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).